After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy developed in partnership with Vertex Pharmaceuticals. Following the ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide. This prevalent condition is also linked to other metabolic disorders, including type 2 ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...